Peripheral Neuropathy Market

Market Insights:

General population studies have reported that 7 to 8% of adults currently have chronic neuropathic pain, where the reported incidence is 8 cases per 1,000 individuals per year. In the U.K. alone, 26% of individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as it is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030.

Anticonvulsant Pregabalin (Lyrica, Pfizer) is among the most widely used drugs for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously reporting cost-benefit analyses to insurers and regulatory bodies. In terms of market competition, the existing brands are continually being expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion.

The report titled “Peripheral Neuropathy Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall peripheral neuropathy market, along with the market size and estimates for the duration of 2017–2025. The research study in question provides an in-depth examination of multiple market segments based on treatment type and geography.

The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies include pain relievers, anti-seizure medications, and antidepressants. Non-pharmacological therapies include transcutaneous electrical nerve stimulation, plasma exchange, intravenous immune globulin, and others (physical therapy and surgery).

Geographically, the global market for peripheral neuropathy is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe
• Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global peripheral neuropathy market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global peripheral neuropathy market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global peripheral neuropathy market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Based on the type of treatment, the global market for peripheral neuropathy is segmented as follows:

• Pharmacological Therapies
• Pain Relievers
• Tramadol
• Oxycodone
• Cyclooxygenase Inhibitors
• Corticosteroid
• Anti-seizure medications
• Gabapentin
• Pregabalin
• Antidepressants
• Amitriptyline
• Doxepin
• Nortriptyline
• Duloxetine
• Venlafaxine
• Non-Pharmacological Therapies
• Transcutaneous electrical nerve stimulation
• Plasma exchange and intravenous immune globulin
• Other (Physical Therapy and Surgery)

Pharmacological therapies are most commonly used and dominate the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizure medications occupied the largest share of the peripheral market at around 41% in 2016, followed by antidepressants and painkillers. Anti-seizure medications include Gabapentin and Pregabalin, which are used as the first line of treatment, with Pregabalin occupying the major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.

For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

At present, North America is observed as having the largest market for peripheral neuropathy. The rising geriatric population and growing incidences of diabetes in the region are the prime factors driving the North American peripheral neuropathy market.

The U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high numbers of research trials on peripheral neuropathy in the country, and high prices of the medication, which generated high revenue. Asia Pacific would exhibit the fastest growth rate in the global peripheral neuropathy market due to an aging population, increasing health awareness, and the high prevalence of diabetes, cancer, and HIV/AIDS.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I – Secondary Research
1.2.2 Phase II – Primary Research
1.2.3 Phase III – Expert Panel Review
1.2.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Peripheral Neuropathy Market Portraiture
2.2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025, (Value %)
2.3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016, (US$ Million)

Chapter 3 Global Peripheral Neuropathy Market Analysis
3.1 Peripheral Neuropathy Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing prevalence of diabetes and cancer
3.2.1.2 Growing preference for non-pharmacological modalities
3.2.2 Challenges
3.2.2.1 Challenge of Developing New Pain Medications for Neuropathic Pain
3.2.2.2 High treatment rate as against low satisfaction indicate gap in treatment
3.2.3 Opportunities
3.2.3.1 Development of drugs with selective targeting of ion channels
3.3 Attractive Investment Proposition
3.4 Market Positioning of Key Players in Global Peripheral Neuropathy Market

Chapter 4 Global Peripheral Neuropathy Market, by Treatment Type
4.1 Overview
4.2 Pharmacological Therapies
4.2.1 Pain Relievers
4.2.1.1 Tramadol
4.2.1.2 Oxycodone
4.2.1.3 Cylcooxgenase Inhibitors
4.2.1.4 Corticosteroid
4.2.2 Anti-seizure medications
4.2.2.1 Gabapentin
4.2.2.2 Pregabalin
4.2.3 Antidepressants
4.2.3.1 Amitriptyline
4.2.3.2 Doxepin
4.2.3.3 Nortriptyline
4.2.3.4 Duloxetine
4.2.3.5 Venlafaxine
4.3 Non-Pharmacological Therapies
4.3.1 Transcutaneous electrical nerve stimulation
4.3.2 Plasma exchange and intravenous immune globulin
4.3.3 Others(Physical Therapy and Surgery)

Chapter 5 Global Peripheral Neuropathy Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia and South Africa)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Bristol Myers Squibb
6.3 Cipla Limited
6.4 Eli Lilly and Company
6.5 GlaxoSmithKline plc.
6.6 Lupin Limited
6.7 Merck and Co. Inc.
6.8 Novartis
6.9 Pfizer Inc.
6.10 Dr. Reddy’s Laboratories

List of Figures

FIG. 1 Global Peripheral Neuropathy Market: Research Methodology
FIG. 2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025 (Value %)
FIG. 3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016 (US$ Million)
FIG. 4 Attractive Investment Proposition: Global Peripheral Neuropathy Market, by Region
FIG. 5 Market Positioning of Key Players: Global Peripheral Neuropathy Market
FIG. 6 Tramadol Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 7 Oxycodone Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 8 Cylcooxgenase Inhibitors Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 9 Corticosteroid Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 10 Gabapentin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 11 Pregabalin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 12 Amitriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 13 Doxepin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 14 Nortriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 15 Duloxetine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 16 Venlafaxine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 17 Transcutaneous Electrical Nerve Stimulation Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 18 Plasma Exchange and Intravenous Immune Globulin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 19 Others (Physical Therapy and Surgery) Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 20 Latin America Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
FIG. 21 Middle East & Africa Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Peripheral Neuropathy Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 2 Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 3 Pain Relievers Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 4 Anti-seizure Medications Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 5 Antidepressant Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 6 Non- Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Peripheral Neuropathy Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 8 North America Peripheral Neuropathy Market , by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Asia-Pacific Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Cipla Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 Eli Lilly and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Lupin Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Merck and Co. Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Novartis: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Pfizer Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Dr. Reddy’s Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)